Analysis
Three venture rounds alone accounted for roughly $2.13 billion in new capital over the past week, and the split says something about where investor conviction actually sits heading into August. Hadrian, the Los Angeles-based automated-factory company, raised $1.37 billion in a Series D at a $7.87 billion valuation -- more than quadrupling its valuation since January -- co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners and JPMorganChase's Strategic Investment Group, according to Axios. Function Health, the preventive-care platform, secured $450 million in growth financing from General Catalyst's Customer Value Fund, per Fierce Healthcare, just eight months after a $298 million Series B, bringing its total raised past $800 million since 2023. And UK-based OLIX Computing closed a $312 million Series B at a $3.3 billion valuation for its photonic AI inference chips -- the largest semiconductor venture round ever raised by a European company.
None of the three dollars went to a foundation-model lab. One went to physical manufacturing capacity, one to a consumer health platform financed through a revenue-share structure rather than pure equity, and one to alternative AI-chip architecture positioned explicitly around avoiding Nvidia's supply constraints. That's consistent with the pattern Pulse has tracked through the summer: model-layer funding gets the attention, but the capital actually flowing into physical capacity, applied verticals and infrastructure alternatives is compounding at a similar scale, often with structures -- like General Catalyst's revenue-share vehicle for Function Health -- that look nothing like a standard equity round anymore.
